WHAT'S HAPPENING IN MY REGION?

Selected region : East
Date: : 24th Mar 2017

Current Studies:

The SEMA-NASH Study: Can a medication called Semaglutide help patients with a non-alcoholic fatty liver disease (Steatohepatitis). NHS Tayside.

Non-alcoholic Steatohepatitis (NASH) is a chronic condition in which the build-up of fat and inflammation in the liver can lead to severe liver damage. Having high levels of fat in your liver is also associated with an increased risk of conditions such as diabetes, heart attacks and strokes. At the moment there are no drugs that are approved for treatment of NASH. The current recommendations advise lifestyle changes to achieve weight loss.

The researchers want to investigate whether a drug called Semaglutide, which is a drug being developed for the treatment of obesity and type 2 diabetes, will improve the condition of the liver in patients with NASH. Eligible participants in this study would be randomly allocated to receive either the study drug or placebo and the participants will not know which of those they will have been given. The researchers will then monitor any improvement in the condition of the liver over a period of 18 months.

The INCOGNITO Trial: Investigating COPD Lung Infections with Different Inhalers. NHS Tayside & NHS Greater Glasgow and Clyde.

Chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide and a major cause of morbidity in the UK. Patients with COPD are frequently prescribed inhalers which contain steroids or bronchodilators to help reduce symptoms. There are a number of different treatments available for patients with COPD, however some treatments that are of benefit to one group of patients may produce side effects in others.

This trial wants to compare two different inhalers that are both already in use for treating COPD. The researchers believe that the two inhalers will have different effects on the bacteria that live in the lungs and inflammation in the lungs. If this is the case, it means that future treatment could be much more effective as doctors will be able to match the right inhaler to the right patient by measuring their levels of inflammation at the start.

If you would like to read more about this study then please click here.

The GoDARTS Study: Genetics of Diabetes Audit and Research in Tayside and Scotland.

This study wants to understand the role our genes, and other biological markers, play in developing and managing diabetes. By conducting this research it will hopefully provide some answers to some of the following questions surrounding the disease; why do some people develop the disease and others don't; why does medication work for some groups of patients with diabetes and not for others and why do some people develop the complications associated with diabetes and others don't.

 The other aim of this study is to look at Metformin, which is one of the most commonly used drugs to treat type 2 diabetes. It can also be used in the treatment of type 1 diabetes in conjunction with insulin therapy. Metformin has been on the market for over 60 years yet its mechanism of action is not fully understood. Some patients respond well to the treatment and encounter very little problems, whilst others find it does not work for them and causes many side-effects.

If you would like to find out more about this study then please click here.

If you are interested in taking part in this study then please have a look at the studies section of our website.

If you wish to hear more about or participate in projects such as those mentioned above please register for SHARE today.

For more information contact us at SHARE@dundee.ac.uk